Biotech startup enters obesity market targeting non-GLP-1 pathways

A new biotechnology firm is developing obesity treatments that bypass the GLP-1 receptor agonist mechanism currently dominating the market. The efficacy and commercial viability of these alternative pathways remain unproven, representing a potential shift in the competitive landscape for weight-loss therapeutics.